Literature DB >> 12385411

Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration.

A Omar1, C Kempf.   

Abstract

BACKGROUND: Nanofiltration has proven to be an effective technology for virus removal. The small nonenveloped viruses, such as HAV and parvovirus B19 (B19), are evidently more difficult to remove than the larger enveloped viruses. However, since antibodies against these viruses, HAV and B19, are constantly present in large plasma pools, it is conceivable that antibody binding will lead to an increase in size of the viruses due to a corona of antibodies on the virus surfaces. These enlarged viruses should be easier to remove by nanofiltration than naked viruses. In this study, antibody-coated viruses and free virions were subjected to nanofiltration to determine whether the antibody-mediated increase in size contributes to the elimination of viruses which are otherwise too small to be retained by filters of a given nominal pore diameter. STUDY DESIGN AND METHODS: One-percent IgG or 1-percent albumin solutions were spiked with bovine enterovirus (BEV) and filtered through 50-nm filters. This virus cross-reacts with antibodies in pooled human IgG solutions but persists as free virions in albumin solutions. Similarly, two parvoviruses, bovine parvovirus (BPV) and minute virus of mice (MVM), in 1-percent IgG solutions were filtered through 20-nm filters. BPV cross-reacts with antibodies in human IgG, whereas MVM remains unaffected. Virus removal was assessed by in vitro infectivity assays. Two methods were developed to displace the antibodies from BEV and BPV and thereby render them accessible for titration.
RESULTS: Antibody-coated BEV was eliminated to below detection limit by the 50-nm filters (logarithmic reduction factors [LRF] > or = 5), while free BEV virions passed without restraint through the same filters. Similarly, antibody-coated BPV was completely retained by the 20-nm filters (LRF > or = 5). MVM virions were strongly retained by the 20-nm filters; however, the virus was still detectable in the filtrate.
CONCLUSION: These results indicate that viruses with bound antibodies are efficiently eliminated by nanofiltration by use of filters having nominal pore sizes larger than the diameter of the respective free virions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12385411     DOI: 10.1046/j.1537-2995.2002.00145.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  10 in total

Review 1.  Recommendations for the transfusion of plasma and platelets.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

Review 2.  Clinical immunology in practice, new opportunities.

Authors:  Mark R Stein
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

3.  Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.

Authors:  Richard L Wasserman; Joseph A Church; Mark Stein; James Moy; Martha White; Steven Strausbaugh; Harry Schroeder; Mark Ballow; James Harris; Isaac Melamed; David Elkayam; William Lumry; Daniel Suez; Syed M Rehman
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

4.  Microscopic visualization of virus removal by dedicated filters used in biopharmaceutical processing: Impact of membrane structure and localization of captured virus particles.

Authors:  Jun Adan-Kubo; Muneo Tsujikawa; Kadue Takahashi; Tomoko Hongo-Hirasaki; Kaoru Sakai
Journal:  Biotechnol Prog       Date:  2019-07-03

Review 5.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

6.  [Viral safety of biologicals].

Authors:  F Barin
Journal:  Ann Pharm Fr       Date:  2008-06-30

7.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

Review 8.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

Review 9.  Emerging infections in transfusion medicine.

Authors:  Eberhard W Fiebig; Michael P Busch
Journal:  Clin Lab Med       Date:  2004-09       Impact factor: 1.935

10.  Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.

Authors:  Nathan J Roth; Herbert O Dichtelmüller; Fabrizio Fabbrizzi; Eckhard Flechsig; Albrecht Gröner; Mary Gustafson; Juan I Jorquera; Thomas R Kreil; Dominika Misztela; Elisa Moretti; Mila Moscardini; Gerhard Poelsler; John More; Peter Roberts; Andreas Wieser; Rodrigo Gajardo
Journal:  Transfusion       Date:  2020-08-19       Impact factor: 3.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.